Clinical Trials Logo

T-cell Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to T-cell Non-Hodgkin's Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05013372 Not yet recruiting - Clinical trials for T-cell Non-Hodgkin's Lymphoma

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Start date: January 2023
Phase: Early Phase 1
Study type: Interventional

The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.

NCT ID: NCT02987244 Recruiting - Clinical trials for T Cell Non-Hodgkin's Lymphoma

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide, epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

NCT ID: NCT00742495 Terminated - Clinical trials for T-cell Non-Hodgkin's Lymphoma

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

BCX1777-108
Start date: March 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Preliminary efficacy will also be assessed.

NCT ID: NCT00655668 Terminated - Clinical trials for T-cell Non-Hodgkin's Lymphoma

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

EXPECT
Start date: March 1, 2008
Phase: Phase 2
Study type: Interventional

This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase. Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable adverse events develop. All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase. Objectives: Primary: • To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell Non-Hodgkin's Lymphoma (NHL). Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time to progression and progression free survival. Secondary: • To evaluate the safety of lenalidomide monotherapy as treatment for subjects with relapsed or refractory T-cell NHL.